Inflazome to bring inflammasome inhibitors to clinic with €40M series B

Inflazome Ltd. (Dublin, Ireland) raised €40 million ($45.7 million) in a series B round Monday, giving it the funds to take several of its inflammasome inhibitors to the clinic next year, including a Parkinson's disease candidate.

New investors Forbion and Longitude Capital led the round; founding investors Novartis Venture Fund and Fountain Healthcare Partners also participated...